CRDF

Cardiff Oncology, Inc. · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website cardiffoncology.com
Employees(FY) 25
ISIN US14147L1089

Performance

-19.43%

-12.76%

+5.42%

-30.3%

+70.95%

YTD

+118.1%

Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Advanced Technical Analysis

Technical Analysis of CRDF 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 43 suggesting a neutral stance, and a Technical Score of 26 reinforcing the overall bearish outlook. This combination signals caution for potential investors as the market appears to be st...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CRDF

Stock Rank

Recent News & Updates

2024-11-18 19:00
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC(Globenewswire)
2024-11-07 03:05
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update(Yahoo Finance)
2024-10-30 04:30
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC(Globenewswire)
2024-08-08 04:05
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update(Yahoo Finance)
2024-08-01 04:05
Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update(Globenewswire)
2024-05-29 04:05
Cardiff Oncology to Present at the Jefferies Healthcare Conference(Globenewswire)
2024-05-13 04:05
Cardiff Oncology to Present at Upcoming Investor Conferences in May(Globenewswire)
2024-05-09 00:15
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036(Prnewswire)
2024-05-06 18:00
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028(Investorplace)
2024-05-02 09:54
CRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024(Investorplace)
2024-05-02 05:45
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates(Zacks)
2024-05-02 04:05
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update(Globenewswire)
2024-04-25 04:05
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update(Globenewswire)
2024-04-08 04:05
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study(Globenewswire)
2024-03-31 20:50
Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why(Zacks)
2024-03-20 19:55
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why(Zacks)
2024-03-13 20:50
Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going(Zacks)
2024-03-13 20:08
Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?(Zacks)
2024-03-06 03:05
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024(Globenewswire)
2024-03-05 23:00
What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now?(Zacks)
2024-02-29 21:12
Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results(Yahoo Finance)
2024-02-29 06:40
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates(Zacks)
2024-02-29 03:07
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update(Globenewswire)
2024-02-29 03:06
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC(Globenewswire)
2024-02-29 03:05
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)(Globenewswire)
2024-02-25 19:00
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference(Globenewswire)
2024-02-21 19:00
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update(Globenewswire)
2024-01-16 21:30
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research(Prnewswire)
2023-11-20 03:05
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference(Prnewswire)
2023-11-02 04:05
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update(Prnewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.